Photodynamische Therapie mit Verteporfin kombiniert mit intravitrealer Injektion von Ranibizumab zur Behandlung okkulter und klassischer choroidaler Neovaskularisationen bei AMD

Translated title of the contribution: Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD

M. M. Maier, N. Feucht, B. Fiore, C. Winkler Von Mohrenfels, P. Kook, C. Fegert, C. Lohmann

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Purpose: The aim of this study is to discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of ranibizumab (0.5 mg) in occult CNV with recent disease progression and in classic choroidal neovascularization (CNV) due to AMD. Methods: In a pilot study in 28 patients (17 classic, 11 occult CNV) an intravitreal injection of ranibizumab was administered within 12 to 24 hours after standard PDT, followed by 2 injections of ranibizumab after 1 and 2 months. Before as well as 3 and 6 months after treatment visual acuity, OCT examinations (retinal thickness) and fluorescein angiography were performed. Results: Mean visual acuity was significantly improved compared to baseline after 3 months (VA baseline 20 / 80, after 3 months 20 / 50, and 20 / 63 after 6 months). We found no choroidal hypoperfusion and no RPE rip. OCT and fluorescein angiography in patients with occult and classic choroidal neovascularisation after the combination therapy showed a reduced retinal thickness (baseline: 307 μ m, after 1 month: 210 μ m, after 3 months: 228 μ m and after 6 months 281 μ m) and a reduction of leakage compared to baseline. Conclusions: Photodynamic therapy combined with injection of intravitreal ranibizumab was well tolerated and is effective. We found a stabilisation of VA in 96 % of patients. Our short-term results are very promising. Further studies are necessary to show the long-term effect of the PDT and anti-VEGF combination therapy.

Translated title of the contributionPhotodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD
Original languageGerman
Pages (from-to)496-502
Number of pages7
JournalKlinische Monatsblatter fur Augenheilkunde
Volume226
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Dive into the research topics of 'Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD'. Together they form a unique fingerprint.

Cite this